中国药业2025，Vol.34Issue(15)：34-40,7.DOI:10.3969/j.issn.1006-4931.2025.15.006
2018年至2023年某院新型抗肿瘤药物临床应用分析
Clinical Application of New Anti-Tumor Drugs in a Hospital from 2018 to 2023
摘要
Abstract
Objective To understand the clinical use of new anti-tumor drugs in a hospital.Methods The drug names,specifications,dosages,and consumption sum of new anti-tumor drugs in the hospital information system(HIS)of the First Affiliated Hospital of Anhui University of Science and Technology from 2018 to 2023 were selected to analyze the annual consumption sum,number of variety,defined daily dose system(DDDs),defined daily dose(DDC),and ranking ratio(B/A).Results The annual consumption sum of new anti-tumor drugs in the hospital increased year by year from 2018 to 2021,but it showed a downward trend from 2022 to 2023 due to the implementation of the"dual channel"designated retail pharmacy policy.The number of varieties has been increasing year by year(from 16 to 48).The DDDs of most new anti-tumor drugs have increased significantly year by year,with osimertinib and imatinib ranking among the top in terms of growth rate.The DDC showed a decreasing trend year by year,and the B/A of most new anti-tumor drugs was close to or greater than 1,indicating a good synchronicity between the overall consumption sum and DDDs.Conclusion The sconsumption sum and DDDs trend of new anti-tumor drugs are consistent with the incidence of tumors,medical insurance policies,and guideline treatment plans.The application of new anti-tumor drugs in the hospital is basically reasonable.关键词
新型抗肿瘤药物/销售金额/用药频度/限定日费用/临床应用分析Key words
new anti-tumor drugs/consumption sum/DDDs/DDC/clinical application analysis分类
医药卫生引用本文复制引用
朱锡玲,王瑾,李伟,张华,田晶晶,王晓娟..2018年至2023年某院新型抗肿瘤药物临床应用分析[J].中国药业,2025,34(15):34-40,7.基金项目
安徽省临床医学研究转化专项项目[202304295107020081] （）
安徽省淮南市科技计划项目[2022212]. （）
